Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy Running title: Anti-AXL mAb for pancreatic cancer immunotherapy

نویسندگان

  • Wilhem Leconet
  • Christel Larbouret
  • Thierry Chardès
  • Gaëlle Thomas
  • Madeline Neiveyans
  • Muriel Busson
  • Marta Jarlier
  • Nina Radosevic-Robin
  • Martine Pugnière
  • Florence Bernex
  • Frédérique Penault-Llorca
  • Jean-Max Pasquet
  • André Pèlegrin
  • Bruno Robert
چکیده

1, INSERM-U896; IRCM; Université Montpellier1; CRLC Val d'Aurelle-Paul Lamarque. 208 rue des Apothicaires. 34298 Montpellier-Cedex5. France 2, Unité de Biostatistiques, CRLC Val d'Aurelle-Paul Lamarque. 208 rue des Apothicaires. 34298 Montpellier-Cedex 5. France 3, Département d'anatomopathologie, centre Jean-Perrin, 58 rue Montalembert, 63000 Clermont-Ferrand, France 4, INSERM-U876; Hématopoïèse Leucémique et Cible Thérapeutique; Université Victor Ségalen; Laboratoire d'hématologie CHU de Bordeaux. 33076 Bordeaux Cedex, France

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Monoclonal Antibody Production Against Vimentin by Whole Cell Immunization in a Mouse Model

Background: Pancreatic carcinoma is the fourth-leading cause of cancer death in the United States and due to its late presentation, only few patients would be candidates for the curative treatment of pancreactomy. Monoclonal antibodies have brought hope to targeted therapy.Objectives: To identify new biomarkers, a panel of monoclonal antibodies was genera...

متن کامل

AXL kinase as a novel target for cancer therapy

The AXL receptor tyrosine kinase and its major ligand, GAS6 have been demonstrated to be overexpressed and activated in many human cancers (such as lung, breast, and pancreatic cancer) and have been correlated with poor prognosis, promotion of increased invasiveness/metastasis, the EMT phenotype and drug resistance. Targeting AXL in different model systems with specific small molecule kinase in...

متن کامل

Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies.

The AXL receptor and its activating ligand, growth arrest-specific 6 (GAS6), are important drivers of metastasis and therapeutic resistance in human cancers. Given the critical roles that GAS6 and AXL play in refractory disease, this signaling axis represents an attractive target for therapeutic intervention. However, the strong picomolar binding affinity between GAS6 and AXL and the promiscuit...

متن کامل

The Role of TAM Family Receptors in Immune Cell Function: Implications for Cancer Therapy

The TAM receptor protein tyrosine kinases-Tyro3, Axl, and Mer-are essential regulators of immune homeostasis. Guided by their cognate ligands Growth arrest-specific gene 6 (Gas6) and Protein S (Pros1), these receptors ensure the resolution of inflammation by dampening the activation of innate cells as well as by restoring tissue function through promotion of tissue repair and clearance of apopt...

متن کامل

Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis.

Repurposing "old" drugs can facilitate rapid clinical translation but necessitates novel mechanistic insight. Warfarin, a vitamin K "antagonist" used clinically for the prevention of thrombosis for more than 50 years, has been shown to have anticancer effects. We hypothesized that the molecular mechanism underlying its antitumor activity is unrelated to its effect on coagulation, but is due to ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2014